Goldman Sachs Group Inc Sesen Bio, Inc. Transaction History

Goldman Sachs Group Inc

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 May 14, 2024	SELL	$0.0 - $0.93 $0 - $287,967	-309,642 Reduced 81.77%	69,014 $29,000
Q3 2022 Nov 10, 2022	SELL	$0.0 - $0.93 $0 - $287,967	-309,642 Reduced 81.77%	69,014 $0
Q2 2022 May 14, 2024	BUY	$0.38 - $0.89 $143,889 - $337,003	378,656 New	378,656 $307,000
Q2 2022 Aug 15, 2022	SELL	$0.38 - $0.89 $13,298 - $31,146	-34,996 Reduced 8.46%	378,656 $307,000
Q1 2022 May 16, 2022	SELL	$0.58 - $0.86 $112,061 - $166,160	-193,210 Reduced 31.84%	413,652 $250,000
Q4 2021 Feb 14, 2022	BUY	$0.73 - $1.28 $294,632 - $516,615	403,606 Added 198.57%	606,862 $495,000
Q3 2021 Nov 10, 2021	BUY	$0.77 - $4.91 $156,507 - $997,986	203,256 New	203,256 $161,000

Ticker SESN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 201,702,000
Market Cap $127M
Description
Sesen Bio, Inc., a late-stage clinical company, focuses on designing, engineering, developing, and commercializing targeted fusion protein therapeutics (TFPTs) for the treatment patients with cancer. Its lead product candidates include Vicineum, a locally-administered targeted fusion protein that is in Phase III clinical trials for the treatment...

Get notified when there are updates to the investment portfolio of Goldman Sachs Group Inc, based on Form 13F filings with the SEC.

Stay updated on Goldman Sachs Group Inc with notifications on news.